Controversy remains over ‘pay for delay’

A tactic used in some drug patent settlement cases is creating renewed controversy concerning so-called “pay for delay.”

The criticism is targeted at agreements in which a large pharmaceutical company pays a competitor to delay introducing a cheaper alternative to the market. The agreement typically occurs after a generic manufacturer tries to market its drug before the patent expires on a b...